The global demand for Pruritus Therapeutics Market is presumed to reach the market size of nearly USD 61.92 MN by 2028 from USD 21.5 MN in 2021 with a CAGR of 6.01% under the study period 2022 - 2028.
Pruritus, also known as itching, is a dermatological disorder. Pruritus is an uncontrollable sensation that prompts scratching to relieve the discomfort. During pruritus, the skin may develop rashes, lumps, or other outward indications of irritation. Some potential causes of itching include dry skin, skin conditions, and pregnancy. Few other conditions that can cause pruritus are food or drug allergies, allergic eczema, psoriasis, urticaria, systemic lupus erythematosus (SLE), chicken pox, etc.
Market Dynamics
The growing prevalence of pruritus-related disorders such as atopic dermatitis, urticaria, and psoriasis is expected to fuel the market expansion. The primary factor for the growth of the pruritus therapeutics market is increasing government initiatives and policies, such as the provision of funds to numerous pharmaceutical and research organizations for the introduction of novel drugs and therapeutics, as well as increased spending on the development of healthcare infrastructure. In addition, the significant demand for over-the-counter topical corticosteroids will offer lucrative development prospects in the pruritus treatment market. Furthermore, the worldwide pruritus therapeutics market is primarily driven by increased research and development activities to develop novel pruritus therapies, current advanced medicines, and the advent of new pharmaceuticals.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pruritus therapeutics. The growth and trends of pruritus therapeutics industry provide a holistic approach to this study.
Market Segmentation
This section of the pruritus therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Class
- Corticosteroids
- Antihistamines
- Counterirritants
- Immunosuppressant
- Calcineurin Inhibitors
- Others
By Indication
- Atopic Dermatitis
- Allergic Contact Dermatitis
- Urticaria
- Psoriasis
- Others
By Route Of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Pruritus Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Pruritus Therapeutics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pruritus therapeutics market include Pfizer Inc., Sanofi S.A., Amgen Inc., Almirall S.A, NJ Novartis Pharmaceuticals Corporation, MC2 Therapeutics A/S, EPI Health LLC, Allergan Plc., Astellas Pharma US, Inc., Mylan N.V., Johnson & Johnson, Vifor Pharma group, Cara Therapeutics Inc., Aventis Pharma Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
